Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
SAR443216 for Cancer
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new drug, SAR4443216, on people with solid tumors that express HER2. The first part of the trial is to determine the maximum tolerated dose (MTD) of the drug, the second part is to expand the dose to a larger group of people to assess preliminary clinical activity.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.